FDA grants IDE approval for Capillary Biomedical’s 7-day-wear infusion set

Capillary Biomedical announced today that it received FDA investigational device exemption (IDE) for its SteadiFlow infusion technology.

Irvine, California–based Capillary Biomedical designed its new SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0